Millennium Management
CADL icon

Millennium Management’s Candel Therapeutics CADL Stock Holding History

Millennium Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.19M Buy
+1,060,086
New +$5.77M ﹤0.01% 2894
2025
Q4 		– Sell
-136,670
Closed -$697K – 6037
2025
Q3 		$697K Buy
+136,670
New +$790K ﹤0.01% 4871
2025
Q2 		– Sell
-208,609
Closed -$1.18M – 5891
2025
Q1 		$1.18M Buy
208,609
+176,983
+560% +$1.45M ﹤0.01% 4235
2024
Q4 		$275K Buy
31,626
+17,914
+131% +$106K ﹤0.01% 5122
2024
Q3 		$95K Sell
13,712
-3,632
-21% -$22.6K ﹤0.01% 5598
2024
Q2 		$108K Buy
+17,344
New +$130K ﹤0.01% 5297
2022
Q4 		– Sell
-14,844
Closed -$47K – 6596
2022
Q3 		$47K Buy
+14,844
New +$50.3K ﹤0.01% 6209
2022
Q1 		– Sell
-13,106
Closed -$102K – 6941
2021
Q4 		$102K Buy
13,106
+2,460
+23% +$23.9K ﹤0.01% 6244
2021
Q3 		$115K Buy
+10,646
New +$88.3K ﹤0.01% 6374

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

Millennium Management's CADL Position: Q1 2026 in Review

Millennium Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 1,060,086 shares worth $5.19M. The stake represents ﹤0.01% of the portfolio and ranks #2894 among its holdings. This is a return to the name: Millennium Management previously reported a position in CADL as recently as Q3 2025.

Millennium Management first reported a position in CADL in Q3 2021 and has held it in 9 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Millennium Management held 1,060,086 shares of Candel Therapeutics worth $5.19M as of Q1 2026.
  • Candel Therapeutics was a new Millennium Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2894 holding.
  • Millennium Management first reported a position in Candel Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.